OKYO Pharma to Present at OIS XV in San Diego

Summary by AI BETAClose X

OKYO Pharma Limited announced its CEO will present at the Ophthalmology Innovation Summit (OIS) XV on November 22, 2025, to discuss urcosimod, a drug candidate for neuropathic corneal pain (NCP). The company is advancing toward a 120-patient multi-center clinical trial for NCP, building on positive Phase 2 results that demonstrated urcosimod's anti-inflammatory and pain-relieving potential for this condition, which currently lacks FDA-approved therapies.

Disclaimer*

UK 100

Latest directors dealings